Compare AbbVie Inc (ABBV) vs ASE Technology Holding Co Ltd (ASX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ASE Technology Holding Co Ltd — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while ASE Technology Holding Co Ltd trades at $40.06 (market cap $89.31B). The key difference: AbbVie Inc is far larger — about 5× ASE Technology Holding Co Ltd's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ASX | |
|---|---|---|
Market Cap | $449.91B | $89.31B |
Sector | Health | Technology |
52-Week High | $261.07 | $45.12 |
52-Week Low | $184.85 | $9.50 |
Enterprise Value | $513.38B | $93.75B |
Dividend Yield | 2.72% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
ASE Technology Holding (ASX) trades at $39.65, down 5.3% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong quarterly earnings beats, with Q1 2026 EPS of $0.20 beating expectations of $0.1703. Revenue grew to $645.39B in 2025, with net income of $40.02B, while valuation ratios like P/E of 67.98 and P/B of 8.67 suggest premium pricing. Recent news highlights AI-driven demand boosting its LEAP advanced packaging business, with 2026 revenue projected above $3.5B.
Outlook remains positive due to AI infrastructure growth and margin expansion, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is 80% buy, with institutional sentiment buoyed by earnings momentum, though the stock's recent decline may reflect profit-taking after a 77.1% three-month surge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →
